Drug Search Results
More Filters [+]

Filibuvir

Alternative Names: filibuvir, pf-00868554, pf00868554, pf 00868554, pf-868554, pf 868554, pf868554
Latest Update: 2023-10-27
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: HCV-NS5B Inhibitor,NN Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Filibuvir

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Hepatitis C|Hepatitis A|Insomnia

Phase 1: Hepatitis A|Hepatitis C|Hepatitis C, Chronic|Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2009-009214-40

P2

Completed

Unknown

2012-01-27

FITNESS

P2

Completed

Hepatitis C|Hepatitis A

2012-01-01

A8121023

P1

Completed

Hepatitis C, Chronic

2011-05-01

A8121008

P1

Completed

Hepatitis C

2011-02-01

Recent News Events